Aggregating data from COVID-19 trials

Affiliations

¹ Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. eogburn@jhsph.edu.
² Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
³ Harvard Medical School, Boston, MA 02115, USA.
⁴ Fielding School of Public Health and Department of Biostatistics, University of California Los Angeles, Los Angeles, CA 90095, USA.
⁵ Swiss Data Science Center, ETH Zürich and EPFL, 1015 Lausanne, Switzerland.
⁶ Department of Biostatistics, University of Florida, Gainesville, FL 32611, USA.
⁷ Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
⁸ Department of Biostatistics, Epidemiology, and Informatics and Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
⁹ Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
¹⁰ Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
¹¹ Johns Hopkins Institute of Clinical and Translational Research, Baltimore, MD 21202, USA.
¹² Covid-19 Collaboration Platform, Boston, MA 02118, USA.
¹³ Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.
¹⁴ Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.

Comment

Elizabeth L Ogburn et al. Science. 2020.

. 2020 Jun 12;368(6496):1198-1199.

doi: 10.1126/science.abc8993.

¹ Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. eogburn@jhsph.edu.
² Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
³ Harvard Medical School, Boston, MA 02115, USA.
⁴ Fielding School of Public Health and Department of Biostatistics, University of California Los Angeles, Los Angeles, CA 90095, USA.
⁵ Swiss Data Science Center, ETH Zürich and EPFL, 1015 Lausanne, Switzerland.
⁶ Department of Biostatistics, University of Florida, Gainesville, FL 32611, USA.
⁷ Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
⁸ Department of Biostatistics, Epidemiology, and Informatics and Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
⁹ Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
¹⁰ Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
¹¹ Johns Hopkins Institute of Clinical and Translational Research, Baltimore, MD 21202, USA.
¹² Covid-19 Collaboration Platform, Boston, MA 02118, USA.
¹³ Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.
¹⁴ Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.

No abstract available

Comment on

A strategic approach to COVID-19 vaccine R&D.
Corey L, Mascola JR, Fauci AS, Collins FS. Corey L, et al. Science. 2020 May 29;368(6494):948-950. doi: 10.1126/science.abc5312. Epub 2020 May 11. Science. 2020. PMID: 32393526 No abstract available.

1. Bassi LL, & Hwenda L (2020). COVID-19: time to plan for prompt universal access to diagnostics and treatments. The Lancet Global Health. - PMC - PubMed
1. Bauchner H, & Fontanarosa PB (2020). Randomized Clinical Trials and COVID-19: Managing Expectations. JAMA. - PubMed
1. Brodwin E and Robbins R (2020, April 23). ‘It’s noisy’: Competing Covid-19 efforts could hamper progress, experts warn. Stat News.
1. Christley RM (2010). Power and error: increased risk of false positive results in underpowered studies. The Open Epidemiology Journal, 3(1).
1. Dean NE, Gsell PS, Brookmeyer R, Crawford FW, Donnelly CA, Ellenberg SS, … & Krause PR (2020). Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. The New England Journal of Medicine, 382 (14), 1366. - PMC - PubMed